Nuvectis Pharma, Inc.
NCM: NVCTLive Quote
📈 ZcoreAI Score
Our AI model analyzes Nuvectis Pharma, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get NVCT Z-Score →About Nuvectis Pharma, Inc.
Healthcare
Biotechnology
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
📊 Fundamental Analysis
Nuvectis Pharma, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -188.0%, which indicates that capital utilization is currently under pressure.
At a current price of $8.22, NVCT currently sits at the 45th percentile of its 52-week range (Range: $5.55 - $11.52).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$217.76M
Trailing P/E
--
Forward P/E
-8.56
Beta (5Y)
-0.21
52W High
$11.52
52W Low
$5.55
Avg Volume
58K
Day High
Day Low